50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#26

Follistatin 344

Muscle GrowthFST-344FollistatinFS-344

A naturally occurring glycoprotein that inhibits myostatin and activin, studied for its potential to promote muscle growth beyond normal genetic limits.

Share:

Overview

Follistatin 344 is the 344-amino acid isoform of follistatin, a naturally occurring glycoprotein that binds to and neutralizes members of the TGF-beta superfamily, most notably myostatin and activin. Myostatin acts as a negative regulator of muscle mass, and by neutralizing it, follistatin removes the brake on muscle growth.

The myostatin-follistatin axis was dramatically demonstrated by Belgian Blue cattle, which carry natural myostatin mutations resulting in extreme muscular development. Rare human myostatin deficiency cases show similar effects. These examples fueled interest in pharmacological myostatin inhibition for therapeutic and performance purposes.

Gene therapy approaches using follistatin have shown remarkable results in animal models of muscular dystrophy. Clinical trials using AAV delivery of follistatin have been conducted in Becker muscular dystrophy and inclusion body myositis patients with promising preliminary results.

Synthetic follistatin 344 as an injectable peptide is distinct from gene therapy. When administered as a recombinant protein, it has a relatively short half-life, limiting sustained myostatin inhibition. Manipulating fundamental growth regulatory pathways carries risks including effects on reproductive function, as activin plays roles in fertility.

Research Uses & Applications

  • Research into myostatin inhibition for muscle growth
  • Investigated for muscular dystrophy treatment via gene therapy
  • Studied for combating sarcopenia and age-related muscle wasting
  • Explored for cachexia management
  • Research into activin modulation for metabolic applications
  • Gene therapy trials for inclusion body myositis

Key Research Findings

  • AAV-delivered follistatin gene therapy showed significant improvements in muscle mass and function in muscular dystrophy animal models.
  • Follistatin-overexpressing mice showed up to 327% increase in muscle mass through combined myostatin and activin inhibition.
  • Clinical gene therapy trials in Becker muscular dystrophy patients showed improved walking distance.
  • Follistatin inhibits multiple TGF-beta family members beyond myostatin, including activin A and GDF-11.
  • Studies in aged animal models showed follistatin partially reversed sarcopenia.

Risks & Side Effects

  • TGF-beta superfamily modulation could affect reproduction, immune function, and tissue homeostasis.
  • Activin inhibition may affect fertility in both sexes.
  • Recombinant follistatin has a short half-life limiting sustained effects.
  • Long-term safety of myostatin inhibition is not fully characterized.
  • Product authenticity can be difficult to verify.

Administration

As a research peptide, administered via subcutaneous injection at 100-300 mcg daily for cycles of 10-30 days. Gene therapy approaches deliver a one-time intramuscular dose via AAV vectors. These are fundamentally different modalities.

Legal Status

Recombinant follistatin 344 is available as a research chemical, not FDA-approved. Gene therapy follistatin delivery is in clinical development under IND protocols. Banned by WADA. Not a controlled substance for research sale.

Frequently Asked Questions

What is Follistatin 344?

A naturally occurring glycoprotein that inhibits myostatin and activin, studied for its potential to promote muscle growth beyond normal genetic limits.

What are the main uses of Follistatin 344?

The primary research applications of Follistatin 344 include: Research into myostatin inhibition for muscle growth; Investigated for muscular dystrophy treatment via gene therapy; Studied for combating sarcopenia and age-related muscle wasting; Explored for cachexia management; Research into activin modulation for metabolic applications; Gene therapy trials for inclusion body myositis.

What are the risks and side effects of Follistatin 344?

Documented risks and side effects include: TGF-beta superfamily modulation could affect reproduction, immune function, and tissue homeostasis.; Activin inhibition may affect fertility in both sexes.; Recombinant follistatin has a short half-life limiting sustained effects.; Long-term safety of myostatin inhibition is not fully characterized.; Product authenticity can be difficult to verify.. Always consult a healthcare professional before considering any peptide.

Is Follistatin 344 legal?

Recombinant follistatin 344 is available as a research chemical, not FDA-approved. Gene therapy follistatin delivery is in clinical development under IND protocols. Banned by WADA. Not a controlled substance for research sale.

How is Follistatin 344 administered?

As a research peptide, administered via subcutaneous injection at 100-300 mcg daily for cycles of 10-30 days. Gene therapy approaches deliver a one-time intramuscular dose via AAV vectors. These are fundamentally different modalities.

Related Peptides

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.